Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Anastrozole benefits confirmed in postmenopausal patients
December 28th, 2004
Postmenopausal women with hormone-sensitive breast cancer receive an increased benefit from treatment with the aromatase inhibitor anastrozole compared with tamoxifen, according to two papers presented December 8, 2004, at the 27th Annual San Antonio Breast Cancer Symposium. Benefits were seen whether anastrozole was given as a primary treatment for 5 years or as an additional treatment after 2 years of tamoxifen. Aromatase inhibitors deplete circulating estrogen in postmenopausal women, shutting down the principal cell signaling pathway in the pathogenesis of breast cancer. Tamoxifen, in comparison, exerts its effect by interacting with the estrogen...
Source: Cancer Weekly (2004-12-28)
|
